Publications by authors named "Matthias Holdhoff"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,509

Total Likes

603

Extended Reach

8,000,823

Social Features

213
V
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Ingo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, Mehdi Touat, Katherine B Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P Mason

N Engl J Med· August 2023

Videos about Article: user user

2 1 4 210 14 262

View All Article and Social Media Activity
R
Risk Factors, Indications, and Effectiveness of Cerebrospinal Fluid Diversion in Patients With High-Grade Glioma-Associated Hydrocephalus: A Systematic Review and Meta-Analysis.
Jovanna A Tracz, Max A Saint-Germain, Cathleen C Kuo, Shahab Aldin Sattari, Joanna M Roy, Matthias Holdhoff

Neurosurgery· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.
Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, Deborah T Blumenthal, Katherine B Peters, Matthias Holdhoff

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM.
Alexander H Pearlman, Yuxuan Wang, Anita Kalluri, Megan Parker, Joshua D Cohen, Matthias Holdhoff

Cancer Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.
Alexander L Ling, Jennifer Gantchev, Michael C Prabhu, Sreyashi Basu, Ryuhjin Ahn, Matthias Holdhoff

Sci Transl Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Fractionated Radiation Therapy as a Chemopotentiator of Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma: A Single-Arm Phase 1/2 Trial.
Timothy Lin, Suqi Ke, Chen Hu, Ryan Assadi, James Huang, Matthias Holdhoff

Int J Radiat Oncol Biol Phys· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium.
Chetan Bettegowda, Houtan Noushmehr, Alessandra Affinito, Manmeet S Ahluwalia, Olaf Ansorge, Matthias Holdhoff

Neuro Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcome Assessment Tools for Evaluating the Management of Gliomas.
Sachiv Chakravarti, Sneha R Gupta, Saket Myneni, Mazin Elshareif, James L Rogers, Matthias Holdhoff

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study.
Kelly Jiang, Anita Kalluri, Michelle Odonkor, Daniel Martinez Heinemann, Carly Weber-Levine, Matthias Holdhoff

World Neurosurg· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pitfalls in 2HG detection with TE-optimized MRS at 3T.
Seyma Alcicek, Dunja Simicic, Lindsay Blair, Max Saint-Germain, Helge J Zöllner, Matthias Holdhoff

medRxiv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.
Kenny K H Yu, Sreyashi Basu, Gerard Baquer, Ryuhjin Ahn, Jennifer Gantchev, Matthias Holdhoff

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.
Craig Horbinski, David A Solomon, Rimas V Lukas, Roger J Packer, Priscilla Brastianos, Matthias Holdhoff

JAMA Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Alterations in Molecularly Defined Oligodendrogliomas.
Carly Weber-Levine, Maureen Rakovec, Kelly Jiang, Anita Kalluri, Divyaansh Raj, Matthias Holdhoff

Neurosurgery· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of human brain cancers using genomic and immune cell characterization of cerebrospinal fluid through CSF-BAM.
Alexander H Pearlman, Yuxuan Wang, Anita Kalluri, Megan Parker, Joshua D Cohen, Matthias Holdhoff

medRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek, Matthias Holdhoff

Sci Transl Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
Jordina Rincon-Torroella, Maureen Rakovec, Anita L Kalluri, Kelly Jiang, Carly Weber-Levine, Matthias Holdhoff

J Neurooncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.
Lucy Chen, Emanuelle Rizk, Mohamed Sherief, Michael Chang, Calixto-Hope Lucas, Matthias Holdhoff

J Neurooncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.
Michael Chang, Mohamed Sherief, Maria Ioannou, Viveka Chinnasamy, Lucy Chen, Matthias Holdhoff

Acta Neuropathol Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value of Engagement in Digital Health Technology Research: Evidence Across 6 Unique Cohort Studies.
Sarah M Goodday, Emma Karlin, Alexa Brooks, Carol Chapman, Christiana Harry, Matthias Holdhoff

J Med Internet Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.
Edina Komlodi-Pasztor, Marta Escarra-Senmarti, Danielle A Bazer, Aastha Bhatnagar, Carlos A Perez Heydrich, Matthias Holdhoff

Front Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation immunodynamics in patients with glioblastoma receiving chemoradiation.
Lindsey Sloan, Rupashree Sen, Chunnan Liu, Michele Doucet, Lee Blosser, Matthias Holdhoff

Front Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng, Matthias Holdhoff

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors.
Kevin Y Zhang, Megan Parker, Carly Weber-Levine, Anita Kalluri, Ignacio Gonzalez-Gomez, Matthias Holdhoff

Acta Neuropathol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek, Matthias Holdhoff

medRxiv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, Burt Nabors, Tobias Walbert

Neurooncol Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR).
Manmeet S Ahluwalia, Ahmad Ozair, Michelle Rudek, Xiaobu Ye, Matthias Holdhoff

Cell Rep Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis